PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1400982
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1400982
Asia Pacific Heparin Market size was valued at USD 1,410 Million in 2022, expanding at a CAGR of 6.0% from 2023 to 2030.
Disorders related to blood clotting are treated with heparin. Heparin is an injectable anticoagulant that is specifically used to stop blood clots in the veins and arteries during surgical procedures. Heparin is also termed as an unfractionated heparin. Heparin is a product of animal origin, obtained from the tissues of meat that has been slaughtered.
Heparin Market- Market Dynamics
Increasing prevalence of cardiovascular disorders is expected to propel market demand
The market for antiplatelet medications is growing at a rapid pace, largely due to the increased prevalence of cardiovascular disorders. Heart disease is the main cause of death in India and China. For instance, according to the National Institutes of Health, it is anticipated that the number of fatalities in India from CVD would increase from 2.26 million in 1990 to 4.77 million in 2020. Over the past few decades, estimates of the prevalence of coronary heart disease in India have varied, with figures ranging from 1.6% to 7.4% in rural areas and from 1% to 13.2% in metropolitan areas.
Heparin Market- Key Insights
As per the analysis shared by our research analyst, the Asia Pacific market is estimated to grow annually at a CAGR of around 6.0% over the forecast period (2023-2030)
Based on Product Type segmentation, unfractionated heparin was predicted to show maximum market share in the year 2022, Unfractionated heparin have gained high demand mainly due to rising disorders caused by injuries or accident fatalities.
Based on Source segmentation, bovine was the leading market in 2022, due to increasing support from FDA for reintroduction of bovine sourced heparin.
Based on Application segmentation, pre-surgical procedures was the leading market in 2022, due to increasing demand from cardiovascular disease treatment.
On the basis of country, China was the leading revenue generator in 2022 mainly due to the growing prevalence of chronic disorders.
The Asia Pacific Heparin Market is segmented on the basis of Product Type, Source, Application, and Region.
The market is divided into three categories based on Product Type: Unfractionated Heparin, Low Molecular Weight Heparin (LMWH) and Ultra-Low Molecular Weight Heparin (ULMWH)). The unfractionated heparin dominates the market. The unfractionated heparin is rising in demand due increasing application across surgical procedures, kidney dialysis and diagnostic tests.
The market is divided into two categories based on Source: bovine, and porcine. The bovine dominates the market and is likely to maintain its dominance during the forecast period. In 2023, FDA encouraged all related manufactures and suppliers of bovine heparin and other animal-sourced products.
The market is divided into five categories based on Application: pre-surgical procedures, post-surgical procedures, kidney dialysis, diagnostic tests, and others. The pre-surgical procedures segment dominates the market and is likely to maintain its dominance during the forecast period. The growing demand for heparin for pre-surgical treatment in chemical industries is mainly boosting the market growth.
Heparin Market- Country Insights
Country wise, this market is widespread into India, China, South Korea, Japan, Australia, Thailand, Indonesia, Philippines, Malaysia, Taiwan, Vietnam, Hong Kong, New Zealand, Singapore, Myanmar, and the rest of the Asia-Pacific (APAC) region.
Stiff government rules governing the approval procedure will affect the rate of market expansion. Further significant obstacle to the market's expansion will come from the increased competition. Moreover, a rise in the quantity of R&D developments undertaken by leading industry participants contributes to the market's expansion. This will present advantageous prospects for the growth of the global heparin market. In addition, an increase in drug launches and approvals will accelerate the market's growth rate.
In January 2022, Optimvia has partnered with Ginkgo Bioworks to enhance its manufacturing capabilities of biosynthetic heparin.
The scope of this report covers the market by its major segments, which include as follows:
ASIA PACIFIC HEPARIN MARKET KEY PLAYERS
Shanghai Fosun Pharmaceutical
Optimvia
Sanofi
Dr Reddy's Laboratories Ltd.
Hebei Changshan Biochemical Pharmaceutical Ltd.
Hepalink Group
Novartis AG
Eisai Co., Ltd.
Nanjing Jianyou Biochemical Pharmaceutical Co. Ltd.
Changzhaou Qianhong Bio-pharma Co., ltd.
Pfizer Inc.
Baxter
GSK
Others
ASIA PACIFIC HEPARIN MARKET, BY PRODUCT TYPE
Unfractionated Heparin
Low Molecular Weight Heparin (LMWH)
Ultra-Low Molecular Weight Heparin (ULMWH)
ASIA PACIFIC HEPARIN MARKET, BY SOURCE
Bovine
Porcine
ASIA PACIFIC HEPARIN MARKET, BY APPLICATION
Pre-surgical procedures
Post-surgical procedures
Kidney dialysis
Diagnostic tests
Others
ASIA PACIFIC HEPARIN MARKET, BY REGION
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Malaysia
Taiwan
Vietnam
Hong Kong
New Zealand
Singapore
Myanmar
Rest of APAC